Notice: Users may be experiencing issues with displaying some pages on stanfordhealthcare.org. We are working closely with our technical teams to resolve the issue as quickly as possible. Thank you for your patience.
Motexafin gadolinium (MGd) has clinical activity in relapsed/refractory low grade lymphomas (LG) and relapsed/refractory chronic lymphocytic leukemia (CLL). 47th Annual Meeting of the American-Society-of-Hematology Kahl, B. S., Advani, R., Kay, N., Lossos, I. S., Evens, A., Gordon, L., MILLER, R. A., Phan, S. C. AMER SOC HEMATOLOGY. 2005: 269B–270B
View details for Web of Science ID 000233426101460